Balance Sheet Dive: Day One Biopharmaceuticals Inc (DAWN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.

After finishing at $16.62 in the prior trading day, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed at $16.42, down -1.20%. In other words, the price has decreased by -$1.20 from its previous closing price. On the day, 0.57 million shares were traded. DAWN stock price reached its highest trading level at $17.14 during the session, while it also had its lowest trading level at $16.345.


Our goal is to gain a better understanding of DAWN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.93 and its Current Ratio is at 10.93. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on April 24, 2024, Reiterated its Buy rating but revised its target price to $33 from $30 previously.

On April 25, 2023, BofA Securities Downgraded its rating to Underperform which previously was Buy and also lowered its target price recommendation from $34 to $9.

On February 08, 2023, CapitalOne started tracking the stock assigning a Overweight rating and target price of $40.CapitalOne initiated its Overweight rating on February 08, 2023, with a $40 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 10 ’24 when Blackman Samuel C. sold 10,000 shares for $16.37 per share. The transaction valued at 163,743 led to the insider holds 1,164,662 shares of the business.

Bender Jeremy sold 9,154 shares of DAWN for $163,417 on May 03 ’24. The CHIEF EXECUTIVE OFFICER now owns 642,602 shares after completing the transaction at $17.85 per share. On May 03 ’24, another insider, York Charles N II, who serves as the COO, CFO AND SECRETARY of the company, sold 8,078 shares for $17.85 each. As a result, the insider received 144,214 and left with 217,293 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 1434942208 and an Enterprise Value of 1117297536.

Stock Price History:

The Beta on a monthly basis for DAWN is -1.45, which has changed by 0.25535166 over the last 52 weeks, in comparison to a change of 0.2644323 over the same period for the S&P500. Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $9.67. The 50-Day Moving Average of the stock is 6.59%, while the 200-Day Moving Average is calculated to be 18.57%.

Shares Statistics:

The stock has traded on average 1.09M shares per day over the past 3-months and 818350 shares per day over the last 10 days, according to various share statistics. A total of 87.23M shares are outstanding, with a floating share count of 60.60M. Insiders hold about 30.65% of the company’s shares, while institutions hold 74.94% stake in the company. Shares short for DAWN as of 1714435200 were 11190943 with a Short Ratio of 10.27, compared to 1711584000 on 8984718. Therefore, it implies a Short% of Shares Outstanding of 11190943 and a Short% of Float of 15.98.

Earnings Estimates

Investors are keenly observing as 9.0 analysts analyze and rate the current performance of Day One Biopharmaceuticals Inc (DAWN) in the stock market.On average, analysts expect EPS of -$0.75 for the current quarter, with a high estimate of -$0.63 and a low estimate of -$0.87, while EPS last year was -$0.61. The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.64 and low estimates of -$0.78.

Analysts are recommending an EPS of between -$2.61 and -$3.08 for the fiscal current year, implying an average EPS of -$2.82. EPS for the following year is -$2.14, with 11.0 analysts recommending between -$1.54 and -$3.0.

Revenue Estimates

For the next quarter, 8 analysts are estimating revenue of $4.72M. There is a high estimate of $6M for the next quarter, whereas the lowest estimate is $3M.

Based on 10 analysts’ estimates, the company’s revenue will be $87.67M in the next fiscal year. The high estimate is $135.23M and the low estimate is $31.1M.

Most Popular

[the_ad id="945"]